Provectus Biopharmaceuticals Announces Investor Webinar For 2025 Annual Meeting Of Stockholders

(MENAFN- GlobeNewsWire - Nasdaq) KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the“Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (the“Annual Meeting”), including shareholder meeting activities and a company update, will also be accessible by Zoom Webinar. The meeting will be held on Wednesday, June 18, 2025, at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.

The webinar of the Annual Meeting may be accessed by registering in advance at:
#/registration .

Annual Meeting materials, including the Company's Proxy Statement, Notice of Internet Availability, and 2024 Annual Report, are available on Provectus's website at .

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecules called halogenated xanthenes. Provectus's lead molecule is named Rose Bengal Sodium.

Provectus's medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov . For additional information about Provectus, please visit the Company's website at .

Forward Looking Statements

The information in this press release may include“forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as“aim,”“likely,”“outlook,”“seek,”“anticipate,”“budget,”“plan,”“continue,”“estimate,”“expect,”“forecast,”“may,”“will,”“would,”“project,”“projection,”“predict,”“potential,”“targeting,”“intend,”“can,”“could,”“might,”“should,”“believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company's filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

• The Company's Annual Report on Form 10-K for the period ended December 31, 2024 , and
• Provectus's Quarterly Report on Form 10-Q for the period ended March 31, 2025 .

Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
(866) 594-5999

Investor Relations & Media
Susan Xu
...
(778) 323-0959

MENAFN09062025004107003653ID1109651400